Moderna, Inc.
MRNA · Price history
Price at last available close
$222.76
+$30.19 (+15.68%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Moderna, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 11, 2026. A research update is not a new financial filing.
Who they are
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah.
How they make money
Moderna is a biotechnology company that develops and commercializes messenger RNA (mRNA) medicines. The company generates revenue primarily through the sale of its mRNA-based vaccines and therapeutic candidates, supported by strategic collaborations and licensing agreements with pharmaceutical partners.
Products & services
Moderna's primary commercial product is its mRNA-based COVID-19 vaccine, including the mNEXSPIKE product launched in 2025. The company also maintains a pipeline of mRNA-based therapeutic candidates for various diseases.
Brands & revenue mix
Leading COVID-19 vaccine product in the U.S. retail channel.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer concentration
The company's revenue is subject to concentration risks related to government and public health agency procurement of COVID-19 vaccines, as disclosed in the 2025 Form 10-K.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — Third-party entities contracted to manufacture, supply, and distribute products, drug substances, and delivery vehicles.Source
Business relationships & partnerships
- Merck — Strategic collaboration for the development and commercialization of mRNA-based cancer vaccines.Source
- Vertex — Strategic collaboration for the development of mRNA-based therapies for cystic fibrosis.Source
- Recordati — Strategic collaboration to globally commercialize Moderna's propionic acidemia candidate.Source
Competitors
Sources
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Total debt increased 73.7% versus the same quarter last year.
Compare the added borrowing with available cash, cash generation and maturities. A percentage increase from a small starting balance can look large without measuring the full debt burden.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
17
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
29
Poor
Financial Strength
30
Business Quality / Moat
50
Management
0
Growth Quality
45
Risk / Durability
10
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
17
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
21/100
Building Historical Record
Model Score 21/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for MRNA
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can MRNA maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can MRNA fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does MRNA's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for MRNA to reach sustainable profitability?
- •What future growth or profitability would be needed to justify MRNA's current valuation?
Essential Investment Snapshot
Wall Street Score
17
Opportunity Score
17
Market Cap
$88.93B
P/E Ratio
-25.0
EPS
$-7.98
52-Week High
$208.90
52-Week Low
$22.28
Beta
0.90
Analyst Target
$122.50
Shares Outstanding
389.0M
Total Revenue
$2.23B
Total Debt
$1.29B
Dividend
No current dividend
Liquidation Value / Share
$17.38
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong upward momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for MRNA
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-307.4x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on MRNA.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary mRNA technology platform.
- +Integrated manufacturing capabilities.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on third-party manufacturing and supply chain.
- −Intellectual property litigation and protection risks.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
17
Oct 1, 2026
Change
-0.1
points
Current Score
17
Oct 5, 2026
Category Changes
MRNA decreased 0.1 points because some fundamentals weakened.
Projected Score
Projected Score
16
Projected Change
-1.0 points
Preliminary comparable-period financial changes suggest decline of approximately 1.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$222.76
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.23B | $1.94B | $3.20B | $6.85B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $2.51B | $868.0M | $1.46B | $4.69B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | -$280.0M | $1.08B | $1.74B | $2.15B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $2.88B | $3.13B | $4.54B | $4.84B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $965.0M | $1.02B | $1.17B | $1.55B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $3.04B | $4.15B | $5.68B | $6.39B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$2.83B | -$2.55B | -$3.39B | -$3.28B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$3.32B | -$3.07B | -$3.94B | -$4.24B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $25.0M | $10.0M | $24.0M | $38.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$3.09B | -$2.77B | -$3.61B | -$3.94B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $64.0M | $54.0M | -$46.0M | $772.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$3.15B | -$2.82B | -$3.56B | -$4.71B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-7.98 | $-7.26 | $-9.27 | $-12.34 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 396M | 389M | 384M | 382M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 396M | 389M | 384M | 382M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$145.0M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$1.96
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+73.7%
Cash Change
+34.7%
Margin Change
+41.7 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, cash levels, net income margin. Pressure indicators included EPS growth, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 2.1%. EPS declined 8.0%. Cash increased 34.7%. Total debt increased 73.7%. Net income margin improved by 41.7 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
Rumor Mill · MRNA
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial